Table 1 Clinical and tumor characteristics of patients with high-risk localized or locally advanced prostate cancer enrolled in our phase II trial
Variable | Cohort 1 (n=18) | Cohort 2 (n=17) | |
|---|---|---|---|
Age, years, median (IQR) | 59 (56–63) | 69 (67–73) | |
Serum PSA level, ng/ml, median (IQR) | 17 (8–26) | 18 (9–28) | |
Clinical T stage, n | T2 | 6 | 5 |
T3 | 12 | 11 | |
T4 | 0 | 1 | |
Clinical N stage, n | N0 | 16 | 15 |
N+ | 2 | 2 | |
Biopsy Gleason score, n | 6 | 3 | 2 |
3+4 | 1 | 2 | |
4+3 | 4 | 7 | |
8-10 | 9 | 6 | |
Pathological T stage*, n | T2c | 2 | NA |
T3a | 3 | ||
T3b | 11 | ||
T4 | 2 | ||
Positive lymph node status, n | 4 | NA | |
Positive surgical margins, n | 8 | NA | |
Pathological Gleason score, n | 8 | 5 | NA |
9 | 13 | ||
Follow up, months, median (IQR) | 61 (45–80) | 63 (26–77) | |